Aratana Therapeutics Inc. (PETX)

3.90
0.09 2.36
NASDAQ : Health Technology
Prev Close 3.81
Open 3.82
Day Low/High 3.76 / 3.94
52 Wk Low/High 3.67 / 7.16
Volume 372.44K
Avg Volume 636.60K
Exchange NASDAQ
Shares Outstanding 48.97M
Market Cap 179.24M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting PETX Call Options For March 15th

Interesting PETX Call Options For March 15th

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PETX options chain for the new March 15th contracts and identified the following call contract of particular interest.

Noteworthy Friday Option Activity: PETX, HRI, PTE

Noteworthy Friday Option Activity: PETX, HRI, PTE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Aratana Therapeutics, Inc , where a total of 2,272 contracts have traded so far, representing approximately 227,200 underlying shares. That amounts to about 54% of PETX's average daily trading volume over the past month of 420,960 shares.

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTB, FII, GVA, MIME, PETX Downgrades: DF, FGEN, MUX, NXGN, PANL, TAIT Initiations: DESP Read on to get TheStreet Quant Ratings' detailed report:

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

Aratana Therapeutics Reports Third Quarter 2018 Financial Results

Aratana Therapeutics Reports Third Quarter 2018 Financial Results

LEAWOOD, Kan., Nov.

Aratana Therapeutics To Report Third Quarter 2018 Financial Results

Aratana Therapeutics To Report Third Quarter 2018 Financial Results

LEAWOOD, Kan., Oct.

First Week Of May 2019 Options Trading For Aratana Therapeutics (PETX)

First Week Of May 2019 Options Trading For Aratana Therapeutics (PETX)

Investors in Aratana Therapeutics, Inc saw new options begin trading this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

3 Great Stocks to Buy If You Love Your Pet

3 Great Stocks to Buy If You Love Your Pet

The animal health market continues to be strong, and so is the outlook. Here are several plays on the space and why you should make them.

RSI Alert: Aratana Therapeutics (PETX) Now Oversold

RSI Alert: Aratana Therapeutics (PETX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Activist Fund Engaged Takes New Position in Cross Country Health

Activist Fund Engaged Takes New Position in Cross Country Health

Glenn Welling took a couple new stakes and maintained large stakes at key targets including Rent-A-Center, Hain Celestial and TiVo.

Oversold Conditions For Aratana Therapeutics (PETX)

Oversold Conditions For Aratana Therapeutics (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aratana Therapeutics Becomes Oversold (PETX)

Aratana Therapeutics Becomes Oversold (PETX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

Sector M&A activity is likely to pick up next year benefiting the space.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

Short Interest In Aratana Therapeutics Jumps 11.7%

Short Interest In Aratana Therapeutics Jumps 11.7%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 384,761 share increase in total short interest for Aratana Therapeutics, Inc , to 3,662,877, an increase of 11.74% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

2 Animal Drugmakers Worth a Sniff

2 Animal Drugmakers Worth a Sniff

Aratana Therapeutics and Kindred Biosciences are promising drug developers in the pet space.

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Commit To Buy Aratana Therapeutics At $5, Earn 6.6% Annualized Using Options

Investors eyeing a purchase of Aratana Therapeutics, Inc stock, but cautious about paying the going market price of $7.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $5 strike, which has a bid at the time of this writing of 20 cents.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

This corrective action has me feeling optimistic about some new opportunities.

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Biotech Movers: Aratana Offering Priced Below Market, Shares Fall

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

TheStreet Quant Rating: D+ (Sell)